Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors

1998 ◽  
Vol 93 (5) ◽  
pp. 763-767 ◽  
Author(s):  
PaoloL. Peghini ◽  
PhilipO. Katz ◽  
NicoleA. Bracy ◽  
DonaldO. Castell
Keyword(s):  
Acid Secretion ◽  
Gastric Acid Secretion ◽  
Gastric Acid ◽  
Proton Pump Inhibitors ◽  
Proton Pump

PREDICTING EFFICACY OF PROTON PUMP INHIBITORS IN REGULATING GASTRIC ACID SECRETION

2004 ◽  
Vol 12 (01) ◽  
pp. 1-34 ◽  
Author(s):  
DHRUV SUD ◽  
IAN M. P. JOSEPH ◽  
DENISE KIRSCHNER
Keyword(s):  
Acid Secretion ◽  
Gastric Acid Secretion ◽  
Gastric Acid ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Acid Reflux ◽  
Published Data ◽  
Turnover Rates ◽  
Long Term Effects ◽  
Dosing Regimens

Developing drugs to treat gastric acid related illnesses such as ulcers and acid reflux disease is the leading focus of pharmaceutical companies. In fact, expenditure for treating these disorders is highest among all illnesses in the US. Over the last few decades, a class of drugs known as a proton pump inhibitors (PPIs) appeared on the market and are highly effective at abating gastric illnesses by raising stomach pH (reducing gastric acid levels). While much is known about the action of PPIs , there are still open questions regarding their efficacy, dosing and long-term effects. Here we extend a previous gastric acid secretion model developed by our group to incorporate a pharmacodynamic/pharmacokinetic model to study proton pump inhibitor (PPI) action. Model-relevant parameters for specific drugs such as omeprazole (OPZ) , lansoprazole (LPZ) and pantoprazole (PPZ) were used from published data, and we conducted simulations to study various aspects of PPI treatment. Clinical data suggests that duration of acid suppression is dependent on proton pump turnover rates and this is supported by our model. We found the order of efficacy of the different PPIs to be OPZ>PPZ>LPZ for clinically recommended dose values, and OPZ>PPZ=LPZ for equal doses. Our results indicate that a breakfast dose for once-daily dosing regimens and a breakfast-lunch dose for twice-daily dosing regimens is recommended. Simulation of other gastric disorders using our model provides atypical applications for the study of drug treatment on homeostatic systems and identification of potential side-effects.

Gastroduodenal Ulceration in Small Animals: Part 2. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists

2017 ◽  
Vol 53 (1) ◽  
pp. 11-23 ◽  
Author(s):  
Evence Daure ◽  
Linda Ross ◽  
Cynthia R. L. Webster
Keyword(s):  
Acid Secretion ◽  
Gastric Acid Secretion ◽  
Gastric Acid ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Evidence Based ◽  
Small Animals ◽  
Clinical Use ◽  
Receptor Antagonists ◽  
Gastroduodenal Ulceration

ABSTRACT In the first part of this review, we discussed the pathophysiology and epidemiology of gastric acid secretion and the epidemiology of gastroduodenal ulceration in dogs and cats. In this section, we discuss the pharmacology and evidence-based clinical use of histamine-2 receptor antagonists and proton pump inhibitors.

scholarly journals Proton pump inhibitors and gastric acid secretion

2001 ◽  
Vol 96 (12) ◽  
pp. 3467-3468 ◽  
Author(s):  
M. Michael Wolfe ◽  
Lynda S. Welage ◽  
George Sachs
Keyword(s):  
Acid Secretion ◽  
Gastric Acid Secretion ◽  
Gastric Acid ◽  
Proton Pump Inhibitors ◽  
Proton Pump

scholarly journals Formulation Development & Evaluation of Buffered Tablet of Proton Pump Inhibitors Drug Rabeprazole Sodium

2019 ◽  
Vol 9 (4-s) ◽  
pp. 315-321
Author(s):  
Mamta Kumari ◽  
Nishi Prakash Jain
Keyword(s):  
Drug Release ◽  
Acid Secretion ◽  
Gastric Acid Secretion ◽  
Gastric Acid ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Water Soluble ◽  
Angle Of Repose ◽  
Formulation Development ◽  
Rabeprazole Sodium

The aim of present study was to prepare buffered tablets of acid labile drug, Rabeprazole sodium for oral administration using buffering agents to protect a drug from gastric fluid. Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell. Rabeprazole blocks the final step of gastric acid secretion. The tablets were prepared by direct compression and wet granulation method. The formulations contain water soluble buffers such as sodium bicarbonate and trisodium phosphate as well as water insoluble buffers as magnesium oxide, magnesium hydroxide and calcium carbonate and crospovidone as superdisintegrant. Preformulation studies like angle of repose, bulk density, tapped density, Carr’s index, hausner’s ratios, DSC and drug/excipient compatibility study were conducted and evaluated for hardness, friability, weight variation, drug content, disintegration and in-vitro dissolution. In the present study, pH of F6 batch was found to be optimum and disintegration time is 42 sec. The drug release was found to show maximum drug release in case of F6 with 99.3% in 60 minutes. In case of stability studies study of the optimized batch, all the results were found to be satisfactory and within limits. There were no significant changes after the period of 1 month study. Keywords: Rabeprazole sodium, Proton-pump inhibitors, Buffered tablet, Superdisintegrants, Buffering agents

Sign in / Sign up

Export Citation Format

Share Document